Changes in peripheral blood lymphocyte subsets during cyclosporin administration in patients with psoriasis vulgaris

European Journal of Dermatology

Volumn 7, Issue 6, 1997, Pages 417-420

  Abe, Masatoshi ^a   Ishikawa, Osamu ^a   Miyachi, Yoshiki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Cyclosporin; Fluorescence activated cell sorter (FACS); Lymphocyte subsets; Psoriasis vulgaris

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; EPIDERMIS CELL; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; PSORIASIS VULGARIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0030885822     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sauder DN, Bailin PL, Sundeen J, Krakauer RS. Suppressor cell function in psoriasis. Arch Dermatol 1980; 116: 51-5.
2. Rubins AY, Merson AG. Subpopulation of T lymphocytes in psoriasis patients and their changes during immunotherapy. J Am Acad Dermatol 1987; 17: 972-7.
3. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-84.
4. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990; 95: 32S-4S.
5. Borel JF, Bauer C, Gubler HU, Stabelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468-75.
6. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1971; 301: 555.
7. Ho VC, Griffiths CEM, Ellis CN, Gupta AK, McCuaig CC, Nickoloff BJ, Cooper KD, Hamilton TA, Voorhees JJ. Intralesional cyclosporin in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol 1990; 22: 94-100.
8. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporin treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989; 21: 91-7.
9. Borel JF. Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 1990; 122 (suppl. 36): 5-12.
10. Griffiths CEM, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986; 293: 731-2.
11. Kato N, Halprin KM, Taylor JR. Cyclosporin A does not inhibit epidermal cell growth at therapeutic levels. J Invest Dermatol 1987; 88: 52-4
12. Sasaki T, Ikezawa Z, Nakajima H. Treatment of severe psoriasis with low dose cyclosporin A and effect on the helper-suppressor T cell ratio in peripheral blood. J Dermatol 1988; 15: 480-6.
13. Picascia DD, Garden JM, Freinkel RK, Roenigk HH. Treatment of resistant severe psoriasis with systemic cyclosporin. J Am Acad Dermatol 1987; 17: 408-14.
14. Nakayama J, Hori Y. Changes of T lymphocyte subset in the peripheral blood of patients with psoriasis with aromatic retinoid administration. Nishinihon J Dermato (in Japanese) 1992; 54: 500-6.
15. Ligresti DJ, Neff JC, Lowney ED. Increased helper-suppressor T cell ratio in psoriasis. Arch Dermatol 1982; 118: 966-70.
16. Takashima A, Morita A. Genomic, phenotypic, and functional analysis of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. J Invest Dermatol 1991; 96: 376-81.